Phaeochromocytoma in Northern Ireland: A 21 Year Review

European Journal of Surgery

Volumn 162, Issue 9, 1996, Pages 695-702

  Beatty, Olivia L ^a   Russell, Colin F J ^a   Kennedy, Laurence ^a   Hadden, David R ^a   Kennedy, Terence L ^a   Atkinson, A Brew ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CATECHOLAMINE; CHLORPROMAZINE; LABETALOL; METOPROLOL; PHENOXYBENZAMINE; PRAZOSIN; PROPRANOLOL;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; ICELAND; MALE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SAFETY; TREATMENT OUTCOME; URINALYSIS;

ADRENAL GLAND NEOPLASMS; CATECHOLAMINES; FEMALE; HUMANS; HYPERTENSION; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NEOPLASM RECURRENCE, LOCAL; NORTHERN IRELAND; PHEOCHROMOCYTOMA; RETROSPECTIVE STUDIES;

EID: 0029849297     PISSN: 11024151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Averbuch SD, Steakley CS, Young RC et al. Malignant phaeochromocytoma: effective management with a combination of cyclophosphamide, vincristine and dacarbazine. Ann Intern Med 1988; 109: 267-273.
2. Bingham W, Elliott J, Lyons SM. Management of anaesthesia for phaeochromocytoma. Anaesthesia 1972; 27: 49-60.
3. Black H, Bursten S. A clinical screening system for detection of patients with phaeochromocytomas. Yale J Biol Med 1984; 52: 259-272.
4. Bravo EL, Tarazi RC, Gifford RW. Circulating and urinary catecholamines in phaeochromocytoma - diagnostic and pathophysiologic implications. N Engl J Med 1979; 301: 682-686.
5. Chatal JF, Charbonnel B. Comparison of iodobenzylguanidine imaging with computed tomography in locating phaeochromocytoma. J Clin Endocrinol Metab 1985; 61: 769-772.
6. Daggett P, Verner I, Carruthers M. Intraoperative management of phaeochromocytoma with sodium nitroprusside. BMJ 1978; 2: 311-313.
7. Desmonts JM, le Houelleur J, Remond P, Duvaldestein P. Anaesthetic management of patients with phaeochromocytoma: a review of 102 cases. Br J Anaesth 1977; 49: 991-998.
8. Duncan M, Compton P, Lazurus L, Smythe G. Measurement of norepinephrine and 3,4-dihydroxyphenylglycol in urine and plasma for the diagnosis of phaeochromocytoma. N Engl J Med 1988; 319: 136-142.
9. Gifford RJ, Kvale W, Maher F, Roth G, Priestley J. Clinical features, diagnosis and treatment of phaeochromocytoma: a review of 76 cases. Mayo Clin Proc 1964; 39: 281-302.
10. Hadden DR, O'Reilly F, Kennedy L, Russell C. Multiple endocrine neoplasia type 2A: a Northern Ireland and Australian family. Henry Ford Hosp Med J 1987; 35: 107-109.
11. Hanson MW, Feldman JM, Beam CA, Leight GS, Coleman RE. Iodine 131-labelled metaiodobenzylguanidine scintigraphy and biochemical analyses in suspected phaeochromocytoma. Arch Intern Med 1991; 151: 1397-1402.
12. Harper MA, Murnaghan GA, Kennedy L, Hadden DR, Atkinson AB. Phaeochromocytoma in pregnancy. Five cases and a review of the literature. Br J Obstet Gynaecol 1989; 96: 594-606.
13. Hull CJ. Phaeochromocytoma. Diagnosis, preoperative preparation and anaesthetic management. Br J Anaesth 1986; 58: 1453.
14. Januszewicz W, Wocial B. Clinical and biochemical aspects of phaeochromocytoma: Report of 110 cases. Cardiology 1985; 72(suppl 1): 131-136.
15. Koshida K, Nishikawa T, Ishida T, Naito K, Hisazumi H. A clinical review of 30 phaeochromocytoma patients. Acta Urol Japan 1988; 34: 592-597.
16. Krempf M, Lumbroso J, Mornex R et al. Use of M-(131I) iodobenzylguanidine in the treatment of malignant phaeochromocytoma. J Clin Endocrinol 1991; 72: 455-461.
17. LCEC Application Note 14. Bioanalytical Systems Inc., West Lafayette, IN 47906, USA.
18. Minno A, Bennett W, Kvale W. Phaeochromocytoma - study of 15 cases diagnosed at autopsy. N Engl J Med 1954; 251: 959-965.
19. Mitty H, Cohen B. Adrenal imaging. Urol Clin North Am 1985; 12: 771-785.
20. Modlin IM, Farndon JR, Shepherd A et al. Phaeochromocytomas in 72 patients: clinical and diagnostic features, treatment and long term results. Br J Surg 1979; 66: 456-465.
21. Modlinger RS, Ertel NH, Hauptman JB. Adrenergic blockade in phaeochromocytoma. Arch Intern Med 1983; 99: 477-479.
22. Morrison PJ, Hadden DR, Hughes AE, Kennedy L, Russell CFJ, Nevin NC. Gene probe analysis in an informative family with multiple endocrine neoplasia syndrome type 2A (MEN 2A). Improvement in carrier risk estimation. Quart J Med 1991; 79: 597-603.
23. Perry LB, Gould AB. The anaesthetic management of phaeochromocytoma. Effect of pre-operative adrenergic blocking drugs. Anaesth Analg 1972; 51: 36.
24. Plouin PF, Chatellier G, Rougeot MA et al. Recent developments in phaeochromocytoma diagnosis and imaging. Adv Nephrol 1988; 17: 275-286.
25. Plouin P, Duclos J, Menard J, Comoy E, Bohuon C, Alexandre J. Biochemical tests for the diagnosis of phaeochromocytoma urinary versus plasma determinations. BMJ 1981; 282: 853-854.
26. Remine W, Chong G, van Heerden J, Sheps S, Harrison E. Current management of phaeochromocytoma. Ann Surg 1974; 179: 740-748.
27. Ross E, Griffith D. The clinical presentation of phaeochromocytoma. Quart J Med 1989; 71: 485-496.
28. Ross EJ, Prichard BNC, Kaufmann L. Preoperative and operative management of patients with phaeochromocytoma. Anaesth Analg 1969; 59: 154-162.
29. Scott HW, Reynolds V, Green N et al. Clinical experience with malignant phaeochromocytomas. Surgery 1984; 96: 1061-1066.
30. Shapiro B. Summary, conclusions and future directions of (iodine 131) metaiodobenzylguanidine therapy in the treatment of neural crest tumors. J Nucl Biol Med 1991; 35: 357-363.
31. Shapiro B, Copp JE, Sisson JC et al. Iodine-131 metaiodobenzylguanidine for the locating of suspected phaeochromocytoma: experience in 400 cases. J Nucl Med 1985; 26: 576-585.
32. Shapiro B, Sisson JC, Lloyd R, Nakajo M, Satterlee W, Beierwaltes WH. Malignant phaeochromocytoma: clinical, biochemical and scintigraphic characterization. Clin Endocrinol 1984; 20: 189-203.
33. Sheps SG. Phaeochromocytoma. In: Spittel JA Jr, Frohnert PP, Sheps SG, eds. Clinical medicine, Vol 7, Philadelphia; Harper and Row, 1984: 1-26.
34. Sheps SG, Jiang N-S, Klee GG. Diagnostic evaluation for phaeochromocytoma. Endocrinol Metab Clin North Am 1988; 17: 397-414.
35. Sheps GG, Jiang N, Klee GC, van Heerden JA. Recent developments in the diagnosis and treatment of phaeochromocytoma. Mayo Clin Proc 1990; 65: 88-95.
36. Stein PP, Black HR. A simplified diagnostic approach to phaeochromocytoma. Medicine 1990; 70: 46-66.
37. Stewart RJ, Anderson JR, Laird JD, Atkinson AB, Kennedy TL. Meta-iodobenzylguanidine in metastatic phaeochromocytoma. Clin Endocrinol 1984; 21: 525-527.
38. Thomas J, Rooke E, Kvale W. The neurologists experience with phaeochromocytoma: a review of 100 cases. JAMA 1966; 197: 100-104.
39. Tucker R, Labarthe D. Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 through 1975. Mayo Clin Proc 1977; 52: 549-555.
40. Van Heerden JA, Sheps SG, Hamberger B, Sheedy PF, Poston JG, Remine WH. Phaeochromocytoma: current status and changing trends. Surgery 1982; 91: 367-372.
41. Warren MJ, Shepstone BJ, Soper N. Iodine-131 metaiodobenzylguanidine (131I-MIBG) for the localisation of suspected phaeochromocytoma. Nucl Med Commun 1989; 10: 467-475.